Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan plus Capecitabine in Asian Subjects with Inoperable Hepatocellular Carcinoma
NCT00635323Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2002
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in hepatocellular carcinoma (HCC), sponsored by Pfizer. Started Nov 2002; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00635323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00635323.